Recruitment for the 15 POLARIS doctoral positions has closed, and the selection process is now underway.
Recruitment for the 15 POLARIS doctoral positions has closed, and the selection process is now underway.


This project has received funding from the European Union’s Horizon Europe research and innovation programme under the Marie Skłodowska-Curie Actions grant agreement No 101311855. This website reflects only the authors’ views, and the European Commission is not responsible for any use that may be made of the information it contains.
© 2026 POLARIS | All Rights Reserved | Powered by Scienseed

Amsterdam UMC is one of the largest health research institutions and university hospitals in the Netherlands, combining patient care, biomedical research and teaching within a single academic environment. It promotes open science, supports doctoral training through its Amsterdam UMC Doctoral School, and fully endorses the principles of the European Charter for Researchers. Within POLARIS, Amsterdam UMC contributes longstanding expertise in leukodystrophy research through the Amsterdam Leukodystrophy Center, with strengths in translational research, clinical trials and sustainable access to therapies for rare diseases.

InnoSer is a European preclinical contract research organisation providing tailored in vitro and in vivo research services to biotechnology and pharmaceutical partners. With facilities in the Netherlands and Belgium, it supports development programmes across several therapeutic areas, including neuroscience and rare diseases. Within POLARIS, InnoSer contributes expertise in preclinical in vivo research and mouse models of rare neurological disorders, with the doctoral candidate position embedded in its R&D team in Leiden.

The Medicines Evaluation Board is the Dutch national authority responsible for the scientific assessment and monitoring of medicines for human and veterinary use. Alongside its regulatory role, it has a strong research focus on regulatory innovation, patient-relevant evidence, rare diseases, advanced therapies and emerging technologies such as personalised medicine and artificial intelligence. Within POLARIS, CBG contributes expertise in regulatory science, access pathways and the development of more adaptive, evidence-informed frameworks connecting scientific innovation to patient benefit.

Vrije Universiteit Amsterdam is a research-intensive university with a strong commitment to academic excellence, open dialogue and societal relevance. Its research spans a broad range of disciplines and is organised around major themes including human health and life sciences, sustainability, digital connectivity and governance. Within POLARIS, VU Amsterdam contributes expertise from its Medicinal Chemistry group, an internationally recognised centre in GPCR research, with particular strengths in ligand design, computational modelling and the development of small molecules and nanobodies.

The University of York is a research-intensive Russell Group university with a strong record in biological sciences and interdisciplinary life-science research. Its research environment supports both fundamental discovery and translation into clinical, industrial and societal impact, and it hosts several doctoral training programmes funded by major UK research councils. Within POLARIS, the University of York contributes expertise in leukodystrophies, zebrafish genetic models and live brain imaging, with the doctoral candidate embedded in the York Biomedical Research Institute.

University College London (UCL) is a leading multidisciplinary university with a strong international reputation for excellence in research, innovation and collaboration. Based in London, UCL brings together expertise across a wide range of disciplines and maintains extensive partnerships with academic, clinical and industrial organisations worldwide. UCL also has a strong track record in European collaborative research, with broad participation in Horizon Europe projects. Within POLARIS, UCL contributes its recognised expertise in neuroscience, genetic therapies and models of rare neurological disease, supporting the development and translation of innovative therapeutic approaches for leukodystrophies.

The Paris Brain Institute is France’s largest neuroscience research institute, bringing together research teams and advanced technology platforms within a highly interdisciplinary environment. Its mission is to accelerate the development of new treatments for disorders of the nervous system by connecting fundamental discovery with translational and clinical research. Within POLARIS, ICM contributes leading expertise in neuroscience, clinical leukodystrophy research and quantitative MRI, supported by its close integration with Pitié-Salpêtrière Hospital and major French research institutions.

Eberhard-Karls-Universität Tübingen, founded in 1477, is a full-faculty research-intensive university in Southern Germany. The Faculty of Medicine and University Hospital Tübingen combines patient care, clinical research, teaching and translational life-science research. Within POLARIS, UKT contributes clinical and scientific expertise in rare pediatric neurogenetic and neurometabolic disorders, with a particular focus on leukodystrophies and lysosomal diseases.

The Cyprus Institute of Neurology and Genetics is a non-profit research, academic and medical centre dedicated to patient care, research and education in neurological and genetic disorders. It brings together specialised clinical and biomedical departments, advanced research infrastructures and an accredited postgraduate school offering MSc and PhD programmes. Within POLARIS, CING contributes expertise in neurology, molecular biology and gene therapy, supported by strong capacities in translational research, doctoral training and research integrity.

The University of Zurich is the largest university in Switzerland and one of Europe’s leading research institutions, combining broad academic excellence with internationally recognised strengths in life sciences, neuroscience and molecular medicine. Within its Faculty of Medicine, the Institute of Pharmacology and Toxicology advances research on disease mechanisms and innovative therapeutic strategies. Within POLARIS, UZH contributes expertise from the Schwank Laboratory in genome editing, RNA biology and synthetic biology, with a focus on translating gene-editing technologies into therapies for genetic and metabolic diseases.

The Hospital del Mar Research Institute is a leading biomedical research institute in Barcelona that manages the translational and clinical research activities of the Parc de Salut Mar. Within POLARIS, HMRIB contributes through its Biomedical Informatics Research Programme (GRIB), which develops advanced computational tools and information technologies for applications in health and life sciences. Its contribution to the network includes strong expertise in translational bioinformatics, predictive modelling and computational approaches to drug discovery.

Vrije Universiteit Brussel is a Flemish university based in Brussels with a strong track record in biomedical innovation. It is the birthplace of nanobody technology, a breakthrough platform that has enabled major advances in biotechnology and medical research as well as several spin-off initiatives. Within POLARIS, VUB contributes expertise through its Molecular Imaging and Therapy research lab, which develops nanobody-based strategies for molecular imaging and therapy, including the targeting and functional study of G protein-coupled receptors.

The Istituto Superiore di Sanità is Italy’s main public research institute in the fields of biomedicine and public health and serves as the technical and scientific body of the Italian National Health Service. Its work spans biomedical research, disease prevention, public health surveillance, training and scientific advice, with a significant role in the field of rare diseases. Within POLARIS, ISS contributes expertise in leukodystrophies, patient-derived cellular models and translational research supporting diagnosis, treatment development and improved care for complex rare conditions.